Aspect Biosystems
Developing bioprinted tissue therapeutics to transform the treatment of currently incurable diseases.
Developing bioprinted tissue therapeutics to transform the treatment of currently incurable diseases.
Aspect Biosystems is a biotechnology startup founded in 2013, headquartered in Canada. The company's slogan encapsulates its mission to develop bioprinted tissue therapeutics for currently incurable diseases. Through its proprietary full-stack tissue therapeutic platform, the company combines bioprinting technology, therapeutic cells, biomaterials, and computational design to create next-generation cell therapies. Aspect aims to address diseases such as type 1 diabetes and genetic and acquired liver diseases. The latest funding came in the form of a Convertible Note investment on April 12, 2023, with Novo Nordisk being the investor. The company's focus on pioneering solutions for unmet medical needs positions it as a promising venture in the biotechnology space. As the landscape for tissue engineering and regenerative medicine continues to evolve, Aspect Biosystems has the potential to make a significant impact in transforming the treatment of debilitating illnesses.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $72.75M | 2 |
|
10 Jul 2024 |
| Convertible Note | Unknown | 1 |
|
12 Apr 2023 |
| Grant | $3.60M | 1 | Pacific Economic Development Canada | 20 Mar 2023 |
| Venture Round | Unknown | 1 |
|
01 May 2022 |
| Grant | Unknown | 2 | Stem Cell Network (SCN), Innovate BC | 02 Mar 2020 |
No recent news or press coverage available for Aspect Biosystems.
We care about your data, and we'd love to use cookies make your experience better.
